HL 2351

Drug Profile

HL 2351

Alternative Names: GX P4; GX-P4 - Genexine; HL2351; Recombinant human interleukin-1 receptor antagonist hybrid Fc; rhIL-1Ra-hyFc

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Genexine
  • Developer Handok Inc
  • Class Anti-inflammatories; Antirheumatics; Biological proteins; Immunoglobulin Fc fragments; Immunoglobulin fusion proteins
  • Mechanism of Action Interleukin 1 receptor antagonists; Interleukin 6 inhibitors; Interleukin-8 expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cryopyrin-associated periodic syndromes
  • Phase I Rheumatoid arthritis

Most Recent Events

  • 03 Jan 2017 Handok Pharmaceuticals terminates a phase II trial in Cryopyrin associated Periodic Syndromes (In children, In adults, In the elderly) in South Korea due to difficulty in recruiting patients (NCT02853084)
  • 31 May 2014 Handok Pharmaceuticals initiates enrolment in a phase I trial in Healthy volunteers in South Korea (NCT02175056)
  • 01 Oct 2013 Phase-I clinical trials in Rheumatoid arthritis in South Korea (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top